Breaking News
October 20, 2018 - Antidepressant treatment may lead to improvements in sleep quality of patients with depression
October 20, 2018 - Study reports increased risk of death in children with inflammatory bowel disease
October 20, 2018 - Number of Autism Genes Now Tops 100
October 20, 2018 - Total diet replacement programmes are effective for treating obesity
October 20, 2018 - CLARIOstar used for fluorescence measurements on CSIRO’s purpose-built research vessel
October 20, 2018 - People with more copies of AMY1 gene digest starchy carbohydrates faster
October 20, 2018 - Case Comprehensive Cancer Center wins NIH grant to study health disparities
October 20, 2018 - Newly discovered compound shows potential for treating Parkinson’s disease
October 20, 2018 - High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients
October 20, 2018 - Immunotherapy medicine found to be effective in treating uveitis
October 20, 2018 - The Pistoia Alliance Calls for Greater Collaboration to Realise Benefits of Innovation and Announces Winners of the 2018 President’s Startup Challenge
October 20, 2018 - Female internists consistently earn less than men
October 20, 2018 - Stanford team looks at dangers of teens’ vaping habits
October 20, 2018 - New approach to understanding cancers will accelerate development of better treatments
October 20, 2018 - LJI and UC San Diego awarded $ 4.5 million as part of NCI’s Cancer Moonshot initiative
October 20, 2018 - School-based HPV vaccination did not increase risky sexual behaviors among adolescent girls
October 20, 2018 - Eye discovery to pave way for more successful corneal transplants
October 20, 2018 - New analysis examines the importance of location in the opioid crisis
October 20, 2018 - Green filters increase reading speed for children with dyslexia
October 19, 2018 - Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM
October 19, 2018 - Better assessments for early age-related macular degeneration
October 19, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum | News Center
October 19, 2018 - Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics
October 19, 2018 - Beckman Coulter Life Sciences announces new research-focused website
October 19, 2018 - Study finds link between refined soluble fibers, gut microbiota and liver cancer
October 19, 2018 - Social media reduces risk of depression among seniors with pain
October 19, 2018 - Newly developed synthetic DNA molecule may one day be used as ‘vaccine’ for prostate cancer
October 19, 2018 - Preoperative weight loss may not provide health benefits after surgery
October 19, 2018 - U.S. Birth Rates Continue to Drop as Age of New Moms Rises
October 19, 2018 - New technology can keep an eye on babies’ movements in the womb
October 19, 2018 - Juul e-cigarettes pose addiction risk for young users | News Center
October 19, 2018 - Gene sequencing reveals crucial molecular aspects of Trypanosoma brucei
October 19, 2018 - New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses
October 19, 2018 - Study shows close link between cytokine interleukin-1ß and obesity-promoted colon cancer
October 19, 2018 - Muscle mass plays a critical role in health, shows research
October 19, 2018 - Study finds undiagnosed prediabetes in many infertile men
October 19, 2018 - The Current issue of “The view from here” is concerned with Nanotherapeutic strategies
October 19, 2018 - Delay in replacing the Pap smear with HPV screening is costing lives
October 19, 2018 - Physicians battle pediatric diseases of ear, nose, throat in Zimbabwe | News Center
October 19, 2018 - Researchers investigate why some cancers affect only young women
October 19, 2018 - Drugmakers funnel millions to lawmakers; a few dozen get $100,000-plus
October 19, 2018 - Unselfish people tend to have more children and receive higher salaries
October 19, 2018 - New findings reveal potential cellular players in tumor microenvironment
October 19, 2018 - Some countries take more time for reimbursement decisions on new cancer drugs
October 19, 2018 - Human brain cell transplant offers insights into neurological conditions
October 19, 2018 - Parental education associated with increased family health care spending
October 19, 2018 - New statistical method estimates long- and short-term risk of recurrence of breast cancer in US women
October 19, 2018 - Father’s exposure to nicotine may cause cognitive deficits in descendants
October 19, 2018 - Could we prevent Alzheimer’s disease by treating herpes?
October 19, 2018 - Nurse-led care can be more successful in managing gout
October 19, 2018 - Trump administration, pharma exchange verbal volleys on drug-price transparency
October 19, 2018 - Duke researchers find way to detect blood doping in athletes
October 19, 2018 - Many primary care doctors are still prescribing sedative drugs for older adults
October 19, 2018 - Finger length can predict sexuality in women say researchers
October 19, 2018 - Study finds differences in side-effects experienced by male and female OG cancer patients
October 19, 2018 - Dysfunction of single gene leads to miscarriages
October 19, 2018 - Few Seniors Who Self-Harm Referred for Mental Health Care
October 19, 2018 - Don’t sweat the sweet stuff
October 19, 2018 - URMC researchers discover new approach to deliver therapeutics to the brain
October 19, 2018 - Speech Pathology Australia raises awareness about Developmental Language Disorder
October 19, 2018 - Middlemen suppliers can increase drug prices and hospital bills, say Johns Hopkins researchers
October 19, 2018 - Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon
October 19, 2018 - Bliss funds research to find whether parental touch can help alleviate pain in premature infants
October 19, 2018 - Human neurons employ highly compartmentalized signaling, study shows
October 19, 2018 - Ultromics expands multiple clinical trials for coronary heart disease to the U.S.
October 19, 2018 - $11 million NIH grant for Clemson University helps launch new center for musculoskeletal research
October 19, 2018 - A new approach identified to control Zika virus, dengue fever
October 19, 2018 - Head Blows Without Concussion May Not Damage Brain, Study Claims
October 19, 2018 - US opioid use not declined, despite focus on abuse and awareness of risk
October 19, 2018 - Next-generation RNA sequencing technology sheds new light on human mitochondrial diseases
October 19, 2018 - UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery
October 19, 2018 - The immune system also plays a key role in day-to-day function of healthy organs
October 19, 2018 - New tool may reveal how the brain structure impacts brain activity, human behavior
October 19, 2018 - Trump Administration announces ‘Winning on Reducing Food Waste’ initiative
October 19, 2018 - For-profit nursing home residents more likely to experience health issues caused by substandard care
October 19, 2018 - Incidence of stroke has risen steadily among marijuana users, show studies
October 19, 2018 - Conceptual framework proposed to examine role of exercise in multiple sclerosis
October 19, 2018 - Near infrared spectroscopy technique for accurate evaluation of chondral injuries
October 19, 2018 - Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions
October 19, 2018 - Shorter physician encounters associated with antibiotic prescribing
Researchers find way to improve immunotherapy drugs’ impact while limiting side effects

Researchers find way to improve immunotherapy drugs’ impact while limiting side effects

image_pdfDownload PDFimage_print

By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the drugs’ impact while limiting treatment-related side effects.

In the last five years, these drugs, known as checkpoint inhibitors, have revolutionized treatment for a wide range of cancers. They can overcome barriers that prevent a patient’s immune system from finding and removing tumor cells. But these drugs, administered through an intravenous drip directly into the blood stream, often trigger troubling autoimmune responses. Two out of three patients receiving this form of immunotherapy have grade-3 or 4 adverse effects. One third of those patients discontinue therapy because of treatment-related problems.

“We wanted to find a more targeted way to give these drugs,” said study author Jeffrey Hubbell, PhD, the Eugene Bell Professor in Tissue Engineering at the University of Chicago. “We felt we could reduce the systemic side effects if we could inject them directly into or around a tumor and, more important, keep them there, concentrating the drug in the place where it ought to go.”

In the November 8, 2017 issue of Science Translational Medicine, Hubbell and colleagues show that injecting the drugs directly into tumor sites reduced systemic side effects and enhanced efficacy. “We weren’t really expecting that both would occur,” Hubbell said. “We were surprised to see such dramatic gains in efficacy.”

The key to improving the performance of these drugs was developing peptides that could anchor the anti-cancer drugs within or adjacent to the tumor environment.

“We had previously discovered a particular peptide sequence that binds to the many components of extra-cellular matrix,” Hubbell said. This led to aggressive screening of related compounds, which led them to a “super-affinity” peptide derived from placenta growth factor-2 (PlGF-2), which has an exceptionally high affinity for extra-cellular matrix proteins.

They were then able to identify the precise part of PlGF-2 (the region 123-144) that does the binding. It links to eight common extra-cellular matrix proteins. So the researchers conjugated the PlGF-2123-144 peptide to the anti-cancer drugs anti-CTLA4 and anti-PD-L1.

Testing in mice showed that both conjugates – PlGF-2123-144 anti-CTLA4 and PlGF-2123-144 anti-PD-L1 – were tethered to the injection site. Very little drug entered the blood stream, where it was barely detectable within three days.

Test results indicate that binding the drugs to the tumor matrix could prevent systemic side effects. Eight out of eight 16-week old non-obese diabetic mice developed autoimmune diabetes after treatment with the standard checkpoint blockade drugs, but none of the mice exposed to the conjugated PlGF-2 checkpoint-blockade drugs developed diabetes.

Further tests on mice showed that the modified drug-antibody model slowed growth of implanted tumors and extended survival. Increasing the dose further slowed tumor growth, boosted the number of cancer-killing T cells entering the tumor environment, and enhanced antitumor activity in nearby tumors.

The modified drugs suppressed tumor growth and prolonged survival in mice with transplanted melanoma and breast cancers. It eradicated breast tumors in 11 out of 16 mice, compared to only five out of 15 mice that responded to treatment with standard anti-CTLA4 and anti-PD-L1.

Only one out of nine mice treated with PlGF-2123-144 anti-CTLA4 and PlGF-2123-144 anti-PD-L1 developed a palpable tumor after being re-challenged with breast tumor cells, an indication that these mice had developed immunologic memory.

“We think we have developed a straightforward way to modify the really important immunotherapy drugs that work remarkably well in some patients but don’t work at all in others,” Hubbell said. “We found that we can enhance efficacy, at least in this mouse model. Perhaps more important, we believe we can reduce the side effects of these remarkable but problematic drugs, allowing patients who need them to remain on the therapy.”

Source:

Novel approach could limit common complications of immunotherapy

Tagged with:

About author

Related Articles